Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in hormonal therapy for acne.

J K L Tan1

  • 1Department of Medicine, University of Western Ontario, London, ON, Canada Windsor Clinical Research Inc, Windsor, ON, Canada.

Skin Therapy Letter
|October 18, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.

The British journal of dermatology·2021
Same author

Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study.

The British journal of dermatology·2018
Same author

Deciphering the enigma of rosacea continues….

The British journal of dermatology·2015
Same author

A global perspective on the epidemiology of acne.

The British journal of dermatology·2015
Same author

Correlation of photographic images from the Leeds revised acne grading system with a six-category global acne severity scale.

Journal of the European Academy of Dermatology and Venereology : JEADV·2012
Same journal

Exosomes in Dermatology.

Skin therapy letter·2026
Same journal

Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.

Skin therapy letter·2026
Same journal

Erratum to: Deuruxolitinib for Alopecia Areata.

Skin therapy letter·2026
Same journal

Advances in the Management of Hyperhidrosis.

Skin therapy letter·2026
Same journal

Topical Ruxolitinib for the Treatment of Hidradenitis Suppurativa.

Skin therapy letter·2026
Same journal

Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis.

Skin therapy letter·2026
See all related articles

Oral contraceptives (OCs) offer an effective treatment for acne in women across all severity levels. Newer formulations containing drospirenone provide dermatologists with an additional option for managing acne and related conditions.

Area of Science:

  • Dermatology
  • Endocrinology
  • Pharmacology

Background:

  • Oral contraceptives (OCs) are recognized treatments for acne vulgaris in women.
  • OCs are suitable for managing acne across its full spectrum of severity.
  • Several OC preparations are approved in Canada for acne treatment, including those for mild-to-moderate and severe cases.

Purpose of the Study:

  • To review the efficacy and safety of oral contraceptives for acne treatment.
  • To highlight the role of newer drospirenone-containing OCs in managing acne and hyperandrogenic disorders.

Main Methods:

  • Literature review of clinical evidence on OCs for acne.
  • Analysis of approved OC formulations in Canada, focusing on ethinyl estradiol and progestin content.
  • Examination of the specific formulation of ethinyl estradiol 0.03 mg and drospirenone 3mg.

Related Experiment Videos

Main Results:

  • OCs containing estrogen (ethinyl estradiol) and a progestin are effective for acne.
  • Four OC preparations are approved in Canada for acne, varying by severity.
  • Drospirenone-containing OCs show accumulating evidence for efficacy and safety.

Conclusions:

  • Oral contraceptives are a valuable therapeutic option for women with acne.
  • The ethinyl estradiol 0.03 mg and drospirenone 3mg formulation presents a new treatment choice for dermatologists.
  • Drospirenone-containing hormonal preparations offer benefits for acne and other hyperandrogenic conditions.